BG63213B1 - Метод за контролиране на сиализацията на протеини, продуцирани от клетъчна култура на бозайници - Google Patents

Метод за контролиране на сиализацията на протеини, продуцирани от клетъчна култура на бозайници Download PDF

Info

Publication number
BG63213B1
BG63213B1 BG102101A BG10210197A BG63213B1 BG 63213 B1 BG63213 B1 BG 63213B1 BG 102101 A BG102101 A BG 102101A BG 10210197 A BG10210197 A BG 10210197A BG 63213 B1 BG63213 B1 BG 63213B1
Authority
BG
Bulgaria
Prior art keywords
cell
tnfri
culture
sialic acid
glycoprotein
Prior art date
Application number
BG102101A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102101A (en
Inventor
Tina Etcheverry
Thomas Ryll
Werner Lesslauer
Thomas Schreitmuller
Wolfgang Richter
Original Assignee
F. Hoffmann- La Roche Ag
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23863440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG63213(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann- La Roche Ag, Genentech, Inc. filed Critical F. Hoffmann- La Roche Ag
Publication of BG102101A publication Critical patent/BG102101A/xx
Publication of BG63213B1 publication Critical patent/BG63213B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG102101A 1995-06-06 1997-12-03 Метод за контролиране на сиализацията на протеини, продуцирани от клетъчна култура на бозайници BG63213B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/469,348 US5705364A (en) 1995-06-06 1995-06-06 Mammalian cell culture process
PCT/US1996/009284 WO1996039488A1 (en) 1995-06-06 1996-06-06 Process for controlling sialylation of proteins produced by mammalian cell culture

Publications (2)

Publication Number Publication Date
BG102101A BG102101A (en) 1998-07-31
BG63213B1 true BG63213B1 (bg) 2001-06-29

Family

ID=23863440

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102101A BG63213B1 (bg) 1995-06-06 1997-12-03 Метод за контролиране на сиализацията на протеини, продуцирани от клетъчна култура на бозайници

Country Status (35)

Country Link
US (1) US5705364A (2)
EP (2) EP0832189B2 (2)
JP (2) JPH11507523A (2)
KR (1) KR100496356B1 (2)
CN (1) CN1166772C (2)
AR (2) AR004940A1 (2)
AT (2) ATE425245T2 (2)
AU (1) AU717847B2 (2)
BG (1) BG63213B1 (2)
BR (1) BR9609150A (2)
CA (1) CA2220684C (2)
CZ (1) CZ293719B6 (2)
DE (2) DE69637867D1 (2)
DK (2) DK0832189T4 (2)
EA (1) EA001215B1 (2)
ES (2) ES2248812T5 (2)
GE (1) GEP20012519B (2)
HU (1) HU226420B1 (2)
IL (1) IL122398A (2)
IS (1) IS2614B (2)
MY (1) MY113496A (2)
NO (1) NO322276B1 (2)
NZ (1) NZ310202A (2)
OA (1) OA10753A (2)
PL (1) PL185484B1 (2)
PT (1) PT1609853E (2)
RO (1) RO120267B1 (2)
SA (1) SA96170351B1 (2)
SI (2) SI0832189T2 (2)
SK (1) SK282658B6 (2)
TR (1) TR199701543T1 (2)
TW (2) TW516962B (2)
UA (1) UA47428C2 (2)
WO (1) WO1996039488A1 (2)
ZA (1) ZA964776B (2)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5705364A (en) † 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
HRP970224A2 (en) * 1996-05-08 1998-04-30 Hoffmann La Roche TREATMENT OF ASTHMA WITH TNFR-Ig
ATE309350T1 (de) * 1997-12-03 2005-11-15 Roche Diagnostics Gmbh Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US6140445A (en) * 1998-04-17 2000-10-31 Crompton Corporation Silane functional oligomer
ES2255765T3 (es) * 1998-05-29 2006-07-01 Genentech, Inc. Procedimiento de cultivo de celulas para la produccion de glicoproteinas.
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
GB9828624D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Production of proteins
KR100475417B1 (ko) * 1998-12-30 2005-07-18 씨제이 주식회사 시알산 함량이 높은 재조합 당단백질의 제조방법
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
US6261805B1 (en) * 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
KR100394474B1 (ko) * 1999-12-18 2003-08-09 동아제약 주식회사 동물세포에서 재조합 당단백질의 연속식 대량생산 방법
ATE313554T1 (de) * 2000-05-16 2006-01-15 Lipoxen Technologies Ltd Derivatisierung von proteinen in wässrigem lösungsmittel
EP1298217A4 (en) * 2000-07-05 2004-09-08 Mitsubishi Pharma Corp Process for the production of a glycoprotein
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
WO2002101019A2 (en) * 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
WO2003083066A2 (en) 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
US20030190710A1 (en) * 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
AU2003300276B2 (en) * 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
AU2004234377A1 (en) * 2003-04-25 2004-11-11 Immunex Corporation Inducers of recombinant protein expression
PL1959011T3 (pl) 2003-10-24 2012-07-31 Selexis Sa Wysokowydajny transfer genu i ekspresja w komórkach ssaczych przez procedurę wielokrotnej transfekcji sekwencji regionu przylegania do macierzy
AU2004309114A1 (en) * 2003-12-23 2005-07-14 Laboratoires Serono Sa Process for the production of tumor necrosis factor-binding proteins
EP1709185A1 (en) * 2003-12-31 2006-10-11 Samyang Genex Corporation Method for mass production of secondary metabolites in plant cell culture by treatment of an alkanoic acid or salt thereof
EP1725673A1 (en) * 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2006128764A2 (en) * 2005-06-03 2006-12-07 Biovitrum Ab (Publ) Process for cultivating animal cells comprising the feeding of plant-derived peptones
KR100670105B1 (ko) 2005-06-29 2007-01-17 주식회사 셀트리온 콩가수분해물의 저분자량 분획을 이용하여 시알산 함량이증가된 에리스로포이에틴을 생산하는 방법 및 그에 의하여생산된 시알산 함량이 증가된 에리스로포이에틴
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PL2253644T3 (pl) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
EP2264061A1 (en) * 2006-01-26 2010-12-22 Recopharma AB Compositions and methods for inhibiting viral adhesion
EP2815768A3 (en) 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
KR101495549B1 (ko) * 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US20080145893A1 (en) * 2006-09-17 2008-06-19 Excellegene Sa Method for producing a recombinant protein at high specific productivity, high batch yield and high volumetric yield by means of transient transfection
WO2008069244A1 (ja) * 2006-12-05 2008-06-12 Kyowa Hakko Kogyo Co., Ltd. 糖蛋白質組成物の製造方法
BRPI0810472A2 (pt) * 2007-04-16 2014-11-11 Momenta Pharmaceuticals Inc Métodos relacionados à glicosilação da superfície celular
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
EP2188371B1 (en) * 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
TWI395593B (zh) * 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
CA2717383C (en) 2008-03-06 2017-01-03 Halozyme, Inc. Large-scale production of soluble hyaluronidase
WO2009126564A1 (en) 2008-04-07 2009-10-15 Bayer Healthcare Llc Methods of recombinant production of glycoproteins
EP2279410B1 (en) 2008-04-22 2015-11-11 The Rockefeller University Methods of identifying anti-inflammatory compounds
MX347112B (es) 2008-09-15 2017-04-12 Genentech Inc Composiciones y metodos para regular osmolaridad celular.
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
EA036569B1 (ru) 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
CN102770458A (zh) * 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
NZ601790A (en) * 2010-02-24 2014-03-28 Zymenex As Process for production and purification of recombinant lysosomal alpha-mannosidase
WO2012017925A1 (ja) 2010-08-02 2012-02-09 協和発酵キリン株式会社 物質の製造方法
WO2012122625A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR101591671B1 (ko) 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CN102839157A (zh) * 2012-07-12 2012-12-26 扬州大学 稳定共表达hST3GalIV和β1-4GalT1的MDCK细胞系及构建方法和应用
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
NO2760138T3 (2) 2012-10-01 2018-08-04
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
HK1218297A1 (zh) 2013-07-06 2017-02-10 Cadila Healthcare Limited 用於生产单克隆抗体的改进方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015128314A1 (en) * 2014-02-27 2015-09-03 F. Hoffmann-La Roche Ag Modulation of cell growth and glycosylation in recombinant glycoprotein production
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
MX2016015971A (es) * 2014-06-03 2017-08-08 Lupin Ltd Proceso de cultivo celular para la producción de una proteína.
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017087882A1 (en) 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
BR112018013501B1 (pt) * 2015-12-29 2022-12-20 N.V. Nutricia Uso de um ingrediente fermentado e oligossacarídeo não digerível
JP7471220B2 (ja) * 2017-11-30 2024-04-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 哺乳動物細胞の培養方法
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
IL300828A (en) 2020-08-31 2023-04-01 Regeneron Pharma Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
JP2024538673A (ja) 2021-10-07 2024-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ｐＨモデリング及び制御のシステム及び方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
JP2025507790A (ja) 2022-03-02 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高力価抗体のための製造プロセス
WO2025219232A1 (en) 2024-04-15 2025-10-23 Evonik Operations Gmbh Application of small peptides supplemented cell culture media for improved cell performance

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926723A (en) 1974-08-08 1975-12-16 Massachusetts Inst Technology Method of controllably releasing glucose to a cell culture medium
JPS5938488B2 (ja) 1979-05-07 1984-09-17 株式会社東芝 空気調和機
ATE55620T1 (de) * 1982-06-21 1990-09-15 Wellcome Found Verfahren zur herstellung von interferon.
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4724206A (en) * 1984-02-13 1988-02-09 Damon Biotech, Inc. Protein production using hypertonic media
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
JPH0639919B2 (ja) 1985-08-29 1994-05-25 トヨタ自動車株式会社 過給機付き内燃機関の異常判別装置
GB8606386D0 (en) * 1986-03-14 1986-04-23 Celltech Ltd Production of protein
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1988001643A1 (en) 1986-08-29 1988-03-10 Endotronics, Inc. Method of culturing cells
JPH01257492A (ja) * 1987-03-05 1989-10-13 Green Cross Corp:The 異種蛋白質の生産増強方法
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
CA1312030C (en) * 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US5151359A (en) * 1988-05-19 1992-09-29 Mitsui Toatsu Chemicals Incorporated Method for producing of human tissue type plasminogen activator
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
KR0132666B1 (en) * 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5096816A (en) * 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) * 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
WO1993010260A1 (en) * 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
JP3523293B2 (ja) † 1993-07-19 2004-04-26 住友製薬株式会社 インターフェロンの産生増強法
US5705364A (en) † 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP5515221B2 (ja) † 2008-01-28 2014-06-11 日油株式会社 ポリオキシエチレンソルビタン脂肪酸エステルの製造方法

Also Published As

Publication number Publication date
SI1609853T2 (sl) 2020-07-31
KR100496356B1 (ko) 2005-11-25
IL122398A0 (en) 1998-06-15
MX9709452A (es) 1998-06-30
KR19990022473A (ko) 1999-03-25
HUP9900920A3 (en) 2001-06-28
HUP9900920A2 (hu) 1999-07-28
ZA964776B (en) 1997-12-08
PL323737A1 (en) 1998-04-14
TW516962B (en) 2003-01-11
ES2248812T3 (es) 2006-03-16
HK1087151A1 (en) 2006-10-06
ES2324046T5 (es) 2020-09-14
ATE425245T2 (de) 2009-03-15
MY113496A (en) 2002-03-30
CN1186514A (zh) 1998-07-01
EP0832189A1 (en) 1998-04-01
SI0832189T2 (sl) 2008-12-31
CA2220684C (en) 2002-11-12
NO975674D0 (no) 1997-12-05
IL122398A (en) 2001-12-23
CZ390997A3 (cs) 1998-06-17
UA47428C2 (uk) 2002-07-15
DE69635076T2 (de) 2006-06-01
EA001215B1 (ru) 2000-12-25
RO120267B1 (ro) 2005-11-30
NO975674L (no) 1998-02-06
SK282658B6 (sk) 2002-11-06
ATE302266T1 (de) 2005-09-15
AU717847B2 (en) 2000-04-06
BR9609150A (pt) 1999-02-23
PT1609853E (pt) 2009-06-09
DK0832189T4 (da) 2008-10-27
CZ293719B6 (cs) 2004-07-14
TR199701543T1 (xx) 1998-05-21
AU6095296A (en) 1996-12-24
IS4626A (is) 1997-12-03
ES2324046T3 (es) 2009-07-29
SK167097A3 (en) 1998-07-08
US5705364A (en) 1998-01-06
ES2248812T5 (es) 2008-12-16
HK1017903A1 (en) 1999-12-03
DK0832189T3 (da) 2005-11-21
DK1609853T4 (da) 2020-04-06
NZ310202A (en) 1999-10-28
HU226420B1 (en) 2008-12-29
AR011439A2 (es) 2000-08-16
JP4348376B2 (ja) 2009-10-21
AR004940A1 (es) 1999-04-07
PL185484B1 (pl) 2003-05-30
DE69635076D1 (de) 2005-09-22
IS2614B (is) 2010-04-15
JP2007190024A (ja) 2007-08-02
NO322276B1 (no) 2006-09-04
JPH11507523A (ja) 1999-07-06
EP0832189B1 (en) 2005-08-17
WO1996039488A1 (en) 1996-12-12
DE69637867D1 (de) 2009-04-23
EP1609853A1 (en) 2005-12-28
EP1609853B2 (en) 2020-01-22
SA96170351B1 (ar) 2006-07-04
EA199700364A1 (ru) 1998-04-30
DK1609853T3 (da) 2009-06-02
SI1609853T1 (sl) 2009-08-31
CA2220684A1 (en) 1996-12-12
GEP20012519B (en) 2001-08-27
SI0832189T1 (sl) 2006-02-28
OA10753A (en) 2002-12-11
EP1609853B1 (en) 2009-03-11
TW426734B (en) 2001-03-21
EP0832189B2 (en) 2008-07-09
DE69635076T3 (de) 2009-01-15
BG102101A (en) 1998-07-31
CN1166772C (zh) 2004-09-15

Similar Documents

Publication Publication Date Title
KR100496356B1 (ko) 포유동물세포배양으로생산되는단백질의시알릴화조절방법
US6656466B1 (en) Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
JP2024517711A (ja) 高シアル酸付加細胞
HK1087151B (en) Process for controlling sialylation of proteins produced by mammalian cell culture
RU2670889C1 (ru) Способ контроля гликозилирования рекомбинантного гликопротеина
CN117242175A (zh) 超唾液酸化细胞
MXPA97009452A (en) Process to control the sialilation of proteins produced by cultivation of mamife cells
HK1017903B (en) Process for controlling sialylation of proteins produced by mammalian cell culture